Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM, respectively. Dri-c21045 is an effective selective inhibitor of CD40-CD40L synergistic stimulator protein-protein interaction (PPI) with IC50 of 0.17 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 31.00 | |
2 mg | In stock | $ 44.00 | |
5 mg | In stock | $ 72.00 | |
10 mg | In stock | $ 122.00 | |
25 mg | In stock | $ 232.00 | |
50 mg | In stock | $ 413.00 | |
100 mg | In stock | $ 618.00 |
Description | Dri-c21045 showed concentration-dependent inhibition of NF-kB activation and all CD40L induced by B cell proliferation with IC50 of 17.1 μM and 4.5 μM, respectively. Dri-c21045 is an effective selective inhibitor of CD40-CD40L synergistic stimulator protein-protein interaction (PPI) with IC50 of 0.17 μM. |
Targets&IC50 | CD40:0.17 µM |
Molecular Weight | 580.61 |
Formula | C32H24N2O7S |
CAS No. | 2101765-81-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2 mg/mL (3.44 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DRI-C21045 2101765-81-3 NF-Κb NF-κB DRI C21045 Tumor Necrosis Factor Receptor DRIC21045 Inhibitor TNFR DRI-C 21045 DRI-C-21045 inhibit TNF Receptor inhibitor